Search

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

Challenges and opportunities in the diagnostics and management of onco-hematological patients under the microscope during tutorial in Russia

Onco-hematology was the focus of the two-day EHA Hematology Tutorial in Moscow, Russia, the third joint tutorial organized by EHA, the National Hematological Society (NHS) and the Russian-Oncohematology Society (ROHS).

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Read more

“Complement-ing” positive outcomes during the COVID-19 pandemic

Dr Dimitrios Mastellos (@dmastellos)

The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.

Read more

More than science: the European Affairs program at EHA2023

To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.

Read more

EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy

Dates: November 23-25, 2017
Location: Amsterdam, The Netherlands
Chair: WE Fibbe, F Dazzi

Organized by:

EHA and the EHA Scientific Working Group on Mesenchymal Stromal Cells

The SWG Meeting “Shaping the future of MSC therapy” brought together basic science, as well as translational and clinical research.…

Read more